KLK3 and prostate carcinoma: Despite good initial clinical responses to ADT (indicated by tumour regression and/or reduced serum PSA), most prostate cancers develop survival strategies that allow them to survive and proliferate in the presence of ADT (Scher and Heller, 2000).